Spotlight on Pediatrics

Evan Dellon, MD, MPH
Credits: 2.0 CME
Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis
Evan Dellon, MD, MPH
The Academy for Continued Healthcare Learning

Hard to Swallow: Bridging Knowledge Gaps in Eosinophilic Esophagitis

Start

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC


Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC


Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO


Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Activity Details

Free CME
2.0 AMA PRA Category 1 Credit(s)
Released: June 4, 2021
Expires: June 4, 2022
120 minutes to complete

Accredited By

Target Audience

This activity is intended for gastroenterologists, allergists, primary care physicians, pediatricians, advanced practice providers, and nurses who care for patients with swallowing disorder.

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Identify patients with EoE using the latest diagnostic recommendations and criteria
  • Outline the reasoning for why EoE must be viewed as a chronic rather than an acute disease
  • Incorporate strategies to facilitate coordinated interdisciplinary EoE care among gastroenterologists, allergists, and nutritionists
  • Evaluate the latest safety and efficacy data with the therapies in clinical trials for EoE
  • Indicate the potential roles of investigational treatments in EoE management plans

Activity Description

Did you know that the incidence of eosinophilic esophagitis (EoE) is increasing rapidly? Are you familiar with the burdens faced by adult and pediatric patients living with EoE? In this multi-module activity led by an interdisciplinary panel, access practical guidance and supplemental resources on the management and treatment of EoE. Navigate at your own pace through video modules and an interactive infographic with animated content and expert commentary.

Faculty discussion will focus on:

  • Recognizing and diagnosing EoE
  • Treating EoE as a chronic disease
  • Novel developments in treatment

Statement of Educational Need

EoE is an immune-mediated, chronic disease that has been steadily increasing in prevalence and incidence over the past 30 years. Clinicians need to understand that the natural history of the EoE consists of chronic inflammation that may progress into fibrous remodeling. Problematically, EoE diagnosis can be challenging for clinicians, and is often considered the last diagnosis. Thus, clinicians need to be more aware of EoE to decrease diagnostic delays. This activity will also raise awareness that EoE is a chronic disease that requires extended therapy and educate clinicians on emerging therapeutic options and the newest guidelines. Finally, clinicians need to improve their multidisciplinary management of EoE to improve outcomes.

Agenda

Video Module - Introduction to EoE and Its Diagnosis
Video Module - EoE: A Chronic Disease With Unmet Treatment Needs
Video Module - It Takes a Village: Interdisciplinary Care for EoE
Interactive Infographic - Practical Points for the Diagnosis and Chronic Treatment of EoE

Faculty

Evan Dellon, MD, MPH
Department of Medicine
Division of Gastroenterology and Hepatology
Adjunct Professor of Epidemiology
Director, CGIBD Biostatistics and Clinical Research Core
Director, Center for Esophageal Diseases and Swallowing
School of Medicine, University of North Carolina at Chapel Hill
Chapel Hill, NC


Raquel Durban, MS, RD, CSP, LDN
Carolina Asthma & Allergy Center
Registered Dietitian
Charlotte, NC


Gary W. Falk, MD, MS
Professor of Medicine
Division of Gastroenterology
University of Pennsylvania Perelman School of Medicine
Philadelphia, PA


Calies Menard-Katcher, MD, MSCS
Associate Professor of Pediatrics
Associate Director of Clinical Research for the GEDP
Division of Gastroenterology Hepatology and Nutrition
Department of Pediatrics
University of Colorado School of Medicine
Gastrointestinal Eosinophilic Diseases Program
Digestive Health Institute
Children's Hospital Colorado
Aurora, CO


Robert Pesek, MD
Medical Director, Asthma
Medical Director, Eosinophilic Gastrointestinal Disorders Clinic
Associate Professor of Pediatrics and Allergy/Immunology
Arkansas Children's Hospital and the University of Arkansas for Medical Sciences
Little Rock, AR


The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

The following financial relationships have been provided:

Evan Dellon, MD, MPH
Consultant (Occasional): Abbott, Adare/Ellodi, Aimmune, Allakos, Amgen, Arena, AstraZeneca, Avir, Biorasi, Calypso, Celgene/Receptos/Bristol Myers Squibb, Celldex, Eli Lilly, EsoCap, GlaxoSmithKline, Gossamer Bio, Parexel, Regeneron, Robarts/Alimentiv, Salix, Sanofi, Shire/Takeda
Grant/Research Support recipient: Adare/Ellodi, Allakos, AstraZeneca, Banner, Celgene/Receptos/Bristol Myers Squibb, GlaxoSmithKline, Holoclara, Meritage, Miraca, Nutricia, Regeneron, Shire/Takeda

Raquel Durban, MS, RD, CSP, LDN
Nothing to disclose

Gary W. Falk, MD, MS
Consultant (Occasional): Allakos, Bristol Myers Squibb, CDX, Cernostics, Ellodi, Ellodi, Lucid, Phathom, Regeneron, Takeda
Grant/Research Support recipient: Allakos, Arena, Bristol Myers Squibb, Interpace, Lucid, Regeneron, Shire/Takeda

Calies Menard-Katcher, MD, MSCS
Nothing to disclose

Robert Pesek, MD
Nothing to disclose

Conflict of Interest Policy/Disclosure Statement

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

This activity will take approximately 120 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 66% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Topical steroids and biologic agents under investigation for EoE

Contact Information for Questions About the Activity

For questions, contact Laurie Novoryta at Lnovoryta@achlcme.org.

Pediatrics Presentations

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
0.25 CME / MOC / CNE / IPCE
RMEI Medical Education, LLC
Challenging Cases of Severe COVID-19: Managing High Risk and Unvaccinated Patients

Challenging Cases of Severe COVID-19: Managing High Risk and Unvaccinated Patients

Start

Activity Details

Free CME/CNE/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: February 28, 2022
Expires: February 27, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19 
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

In this activity, an interprofessional panel discusses 2 real-world cases of severe COVID-19 submitted by our learners and offers their insight on how to best approach their care.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA


Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: February 28, 2022
Expires: February 27, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Incorporate emergency use authorization status and available clinical trial data into the selection of treatment for patients hospitalized with COVID-19 
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

In this activity, an interprofessional panel discusses 2 real-world cases of severe COVID-19 submitted by our learners and offers their insight on how to best approach their care.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA


Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
0.25 CME / MOC / CNE / IPCE
RMEI Medical Education, LLC
Challenging Cases of Severe COVID-19: Unlikely Patients and Breakthrough Infections

Challenging Cases of Severe COVID-19: Unlikely Patients and Breakthrough Infections

Start

Activity Details

Free CME/CNE/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: February 28, 2022
Expires: February 27, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess disease severity and implications in patients with COVID-19 
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

When we think of severe COVID-19 infection, we often do not think of the young and otherwise healthy. In this activity, an interprofessional panel of experts dive into discussion on some unlikely severe COVID-19 cases and breakthrough infections as submitted directly by clinicians from all over the country.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA


Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/CNE/IPCE/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC Contact Hour(s)
0.25 IPCE Credit(s)™
0.25 ABIM MOC Point(s)
Released: February 28, 2022
Expires: February 27, 2023
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, hospital medicine, infectious disease, internal medicine, and pediatric clinicians (MD/NP/PA/Nurses) involved in the treatment of patients with severe COVID-19 infection.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Assess disease severity and implications in patients with COVID-19 
  • Integrate the unique roles and responsibilities of interprofessional care team members in the management of severe COVID-19 in hospitalized patients

Activity Description

When we think of severe COVID-19 infection, we often do not think of the young and otherwise healthy. In this activity, an interprofessional panel of experts dive into discussion on some unlikely severe COVID-19 cases and breakthrough infections as submitted directly by clinicians from all over the country.

Chair

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI
Director, Clinical Infectious Diseases Research and MultiSpecialties
Clinical Associate Professor, Medicine (Tulane University)
Associate Professor, University of Queensland/Ochsner Clinical School, Brisbane, Australia
Ochsner Health
New Orleans, LA


Faculty

Thomas F. Patterson, MD, FACP, FIDSA
Chief, Division of Infectious Diseases
Vice-Chair, Faculty Development
Professor, Medicine
Director, San Antonio Center for Medical Mycology
UT Health San Antonio
San Antonio, TX


Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN
Advanced Practice Provider, Pulmonary Critical Care
Chairperson, System Critical Care Integration Council
Ochsner Medical Center
Ochsner Health
New Orleans, LA


Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Julia B. García-Díaz, MD, MSc, FACP, FIDSA, CPI,
has no relevant financial relationships with ineligible companies to disclose.

Thomas F. Patterson, MD, FACP, FIDSA, has relevant financial relationships with Appili, Basilea, Gilead, Mayne, Merck, Pfizer, Scynexis, Sfunga (Consultant); Cidara, F2G (Researcher).

Fiona A. Winterbottom, DNP, MSN, APRN, ACNS-BC, ACHPN, CCRN, has relevant financial relationships with Baxter (Advisor); Zoll (Speaker/Speaker’s Bureau).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.


Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit

Physicians claiming ABIM MOC points must provide ABIM ID and month/date of birth and score 100% on the post-test.

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Richard A. Elion, MD
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 10: Weight Gain and Other Adverse Events

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 10: Weight Gain and Other Adverse Events

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 9, 2022
Expires: February 9, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions

Activity Description

As ART options continue to evolve, clinicians learn more about their adverse events. Recently, weight gain has come to the forefront and clinicians struggle to balance the impact of weight gain on patient health with efficacy of ART regimens. Dr. Richard A. Elion and Dr. Todd T. Brown discuss a patient who needs to switch regimens because of neuropsychiatric adverse events and is concerned about weight gain. Data about weight gain associated with certain ART regimens, risk factors for weight gain, impact on risk for cardiovascular disease, and strategies to balance the risk for neuropsychiatric adverse events and potential for weight gain when selecting a new ART regimen.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia


Todd T. Brown, MD, PhD
Professor of Medicine
Johns Hopkins University
Baltimore, Maryland

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Todd T. Brown, MD, PhD: Nothing to disclose

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 9, 2022
Expires: February 9, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug-drug interactions

Activity Description

As ART options continue to evolve, clinicians learn more about their adverse events. Recently, weight gain has come to the forefront and clinicians struggle to balance the impact of weight gain on patient health with efficacy of ART regimens. Dr. Richard A. Elion and Dr. Todd T. Brown discuss a patient who needs to switch regimens because of neuropsychiatric adverse events and is concerned about weight gain. Data about weight gain associated with certain ART regimens, risk factors for weight gain, impact on risk for cardiovascular disease, and strategies to balance the risk for neuropsychiatric adverse events and potential for weight gain when selecting a new ART regimen.

Faculty

Richard A. Elion, MD
Clinical Professor of Medicine
George Washington University, School of Medicine
Washington, District of Columbia


Todd T. Brown, MD, PhD
Professor of Medicine
Johns Hopkins University
Baltimore, Maryland

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Richard A. Elion, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc., ViiV Healthcare; Speakers Bureaus: Gilead Sciences, Inc., ViiV Healthcare; Other: Work with Trio Health doing research funded by multiple companies

Todd T. Brown, MD, PhD: Nothing to disclose

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Sharon L. Walmsley, MSc, MD, FRCPC
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 11: Intersection of COVID-19 and HIV

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 11: Intersection of COVID-19 and HIV

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 9, 2022
Expires: February 9, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

As the COVID-19 pandemic continues to evolve, clinicians often have questions about special considerations for their patients with HIV, including details about anti-SARS-CoV-2 monoclonal antibodies, vaccines, and ART regimens. Dr. Sharon L. Walmsley and Dr. Karine Lacombe discuss a patient newly diagnosed with HIV who recently contracted COVID-19 and whether the patient is eligible for anti-SARS-CoV-2 monoclonal antibodies, timing of both COVID-19 and flu vaccinations, and how to initiate an ART regimen.

Faculty

Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada


Karine Lacombe, MD, PhD
Associate Professor
Infectious and Tropical Diseases
Saint-Antoine Hospital
Professor
Sorbonne University Medical School
Paris, France

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare

Karine Lacombe, MD, PhD: Consulting Fees: Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Janssen Global Services, LLC, ViiV Healthcare Limited

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 9, 2022
Expires: February 9, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Optimize ART regimens and clinical practice to address needs of specific patient populations, such as women with HIV, transgender patients, or patients with substance use disorder

Activity Description

As the COVID-19 pandemic continues to evolve, clinicians often have questions about special considerations for their patients with HIV, including details about anti-SARS-CoV-2 monoclonal antibodies, vaccines, and ART regimens. Dr. Sharon L. Walmsley and Dr. Karine Lacombe discuss a patient newly diagnosed with HIV who recently contracted COVID-19 and whether the patient is eligible for anti-SARS-CoV-2 monoclonal antibodies, timing of both COVID-19 and flu vaccinations, and how to initiate an ART regimen.

Faculty

Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada


Karine Lacombe, MD, PhD
Associate Professor
Infectious and Tropical Diseases
Saint-Antoine Hospital
Professor
Sorbonne University Medical School
Paris, France

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare

Karine Lacombe, MD, PhD: Consulting Fees: Gilead Sciences, Inc., Merck Sharp & Dohme Corp., Janssen Global Services, LLC, ViiV Healthcare Limited

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Sharon L. Walmsley, MSc, MD, FRCPC
0.25 CME / CNE
Postgraduate Institute for Medicine
Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 12: HIV and CVD

Answers to Everyday Practice Challenges in HIV Medicine: A Phone-a-Friend Peer Consult Series—Module 12: HIV and CVD

Start

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 9, 2022
Expires: February 9, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug–drug interactions

Activity Description

As patients with HIV continue to live longer, there is a greater concern of comorbidities typically seen in aging patients, such as cardiovascular disease (CVD). Patients with HIV have an increased risk of CVD and HIV specialists should feel prepared to address this risk with their patients and to tailor both ART and other medications. Dr. Sharon L. Walmsley and Dr. Priscilla Hsue discuss a patient with several risk factors for CVD, including the risk of CVD in HIV, the relationship between ART and CVD, drug–drug interactions, strategies to estimate risk, and initiating treatment for common risk factors, such as hypercholesterolemia.

Faculty

Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada


Priscilla Hsue, MD
Professor of Medicine
University of California San Francisco
Chief of the Division of Cardiology
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare

Priscilla Hsue, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc.; Contracted Research: Novartis International AG

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Activity Details

Free CME/CNE
0.25 AMA PRA Category 1 Credit(s)
0.25 Contact Hour(s)
Released: February 9, 2022
Expires: February 9, 2023
15 minutes to complete

Provided By

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

Target Audience

The educational design of this enduring activity addresses the needs of HIV-specialist physicians and other clinicians and stakeholders involved in the care of patients with HIV infection.

Learning Objective

After completing this activity, the participant should be better able to:

  • Tailor ART regimens according to patient comorbidities, risk factors, adverse events, and drug–drug interactions

Activity Description

As patients with HIV continue to live longer, there is a greater concern of comorbidities typically seen in aging patients, such as cardiovascular disease (CVD). Patients with HIV have an increased risk of CVD and HIV specialists should feel prepared to address this risk with their patients and to tailor both ART and other medications. Dr. Sharon L. Walmsley and Dr. Priscilla Hsue discuss a patient with several risk factors for CVD, including the risk of CVD in HIV, the relationship between ART and CVD, drug–drug interactions, strategies to estimate risk, and initiating treatment for common risk factors, such as hypercholesterolemia.

Faculty

Sharon L. Walmsley, MSc, MD, FRCPC
Director of Clinical Research
Immunodeficiency Clinic
Toronto Hospital, University Health Network
Professor
University of Toronto Department of Medicine
Senior Scientist
Toronto General Hospital Research Institute
Co-Chair of the CIHR Canadian HIV Trials Network
Toronto, Ontario, Canada


Priscilla Hsue, MD
Professor of Medicine
University of California San Francisco
Chief of the Division of Cardiology
Zuckerberg San Francisco General Hospital and Trauma Center
San Francisco, California

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CME/CE activity:

Sharon L. Walmsley, MSc, MD, FRCPC: Consulting Fees: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare; Contracted Research: Gilead Sciences, Inc., Janssen Global Services, LLC, Merck & Co., Inc., ViiV Healthcare

Priscilla Hsue, MD: Consulting Fees: Gilead Sciences, Inc., Merck & Co., Inc.; Contracted Research: Novartis International AG

The PIM planners and others have nothing to disclose. The Integritas Communications planners and others have nothing to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.

Designation of Credit

Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Instructions for Receiving Credit

To receive credit for this activity, participants must complete the preactivity questionnaire, complete and receive a score of 100% on the posttest, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from Gilead Sciences, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

CME Questions – PIM Contact Information
For information about the accreditation of this program, please contact PIM via email at inquiries@pimed.com or at http://www.pimed.com/.

Integritas Contact Information
For all other questions regarding this activity, please contact Integritas via email at info@exchangecme.com.

Reynold A. Panettieri, Jr, MD
1.0 AANP / CME
Global Education Group
Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma

Case-in-Point™ − Cause for Alarm: New Avenues to the Management of Severe Asthma

Start

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 AANP Contact Hour(s)
Released: January 18, 2022
Expires: January 18, 2023
60 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
  • Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
  • Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
  • Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Activity Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.

Moderator

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey


Faculty

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona


Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.

Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

Accreditation Council for Pharmacy EducationThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Activity Details

Free CME/AANP
1.0 AMA PRA Category 1 Credit(s)
1.0 AANP Contact Hour(s)
Released: January 18, 2022
Expires: January 18, 2023
60 minutes to complete

Provided By

This activity is jointly provided by Global Education Group and Integritas Communications.

Target Audience

This activity addresses the needs of clinical immunologists, pulmonologists, and other physicians involved in the management of patients with severe asthma.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Describe clinically relevant pathophysiologic processes in severe asthma, including implications for new targeted treatment options
  • Comprehensively assess patients with asthma for disease severity, lung function, and treatment responses
  • Discuss the mechanisms of action and clinical profiles of new and emerging targeted therapies for severe asthma
  • Individualize treatment regimens for patients with severe asthma based on symptoms, phenotypes, and patient preferences

Activity Description

Best practices within the management of severe asthma require the integration of evidence-based guidelines, the latest scientific information, and an accumulation of clinical experience—all of which inform individualized treatment selection and chronic care decisions. To better mirror real-world practice, this Case-in-Point™ severe asthma enduring program will utilize a case-based format to actively engage learners while emphasizing knowledge consolidation and translation. Within the context of these representative, challenging case studies, a multidisciplinary panel of expert faculty will review and discuss key topics including newer insights into type 2 (T2) high and T2 low asthma pathophysiology, the longitudinal assessment of severe disease, and the latest evidence and rationale for the implementation of available and emerging targeted therapies.

Moderator

Reynold A. Panettieri, Jr, MD
Professor of Medicine, Robert Wood Johnson Medical School
Vice Chancellor, Translational Medicine and Science
Director, Rutgers Institute for Translational Medicine and Science
Emeritus Professor of Medicine, University of Pennsylvania
Child Health Institute of New Jersey
Rutgers, The State University of New Jersey
New Brunswick, New Jersey


Faculty

Monica Kraft, MD
Professor of Medicine
Chair, Department of Medicine
The Robert and Irene Flinn Endowed Chair in Medicine
University of Arizona (UA) College of Medicine – Tucson
Deputy Director, UA Health Sciences Asthma and Airway Disease Research Center
Tucson, Arizona


Anju T. Peters, MD, MS
Professor of Medicine
Department of Allergy and Immunology
Department of Otolaryngology – Head and Neck Surgery
Director of Clinical Research
Division of Allergy and Immunology
Northwestern University Feinberg School of Medicine
Chicago, Illinois


Disclosure of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Reynold A. Panettieri, Jr, MD: Consulting Fee: AstraZeneca plc, Bayer AG, Genentech, Inc., Teva Pharmaceutical Industries Ltd.; Contracted Research: ACTIV-1, AstraZeneca plc, Genentech, Inc., Janssen Pharmaceuticals, Medimmune, LLC, Novartis International AG, Origo Biopharma, Teva Pharmaceutical Industries Ltd., Vault Health, Inc.; Speakers Bureau: AstraZeneca plc, Genentech, Inc., Merck & Co., Inc., Sanofi S.A.

Monica Kraft, MD: Consulting Fee: AstraZeneca plc, Sanofi S.A.; Contracted Research: ALA Pharma Ltd., AstraZeneca plc, Chiesi USA, Inc., Sanofi S.A.

Anju T. Peters, MD, MS: Consulting Fee: AstraZeneca plc, GlaxoSmithKline, Novartis International AG, Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.; Contracted Research: AstraZeneca plc, Merck & Co., Inc., Optinose US, Inc., Regeneron Pharmaceuticals, Inc., Sanofi S.A.

The following planners and managers have reported no relevant financial relationships with ineligible companies:

Kristin Delisi, NP, Lindsay Borvansky, Andrea Funk, Liddy Knight, Ashley Cann, Celeste Collazo, MD, Rose O’Connor, PhD, CHCP, Jim Kappler, PhD

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Integritas Communications. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

Global designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse Practitioner Continuing Education

Accreditation Council for Pharmacy EducationThis activity has been planned and implemented in accordance with the Accreditation Standards of the American Association of Nurse Practitioners (AANP) through the joint providership of Global Education Group and Integritas Communications. Global Education Group is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 110121. This activity is approved for 1.0 contact hour(s) (which includes 0.2 hour(s) of pharmacology).

Instructions for Receiving Credit

In order to receive credit for this activity, the participant must complete the preactivity questionnaire, score 75% or better on the post-test, and complete the program evaluation.

Statement of Commercial Support

This activity is supported by an independent educational grant from AstraZeneca.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Term of Offering

This activity was released on January 18, 2022, and is valid for one year. Requests for credit must be made no later than January 18, 2023.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Contact Information for Questions About the Activity

Global Contact Information
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Cassandra Calabrese, DO
0.5 CME / MOC / CPE
Vindico Medical Education
Pneumococcal Disease: Prevalence and Prevention – A Wheel of Knowledge Challenge!

Pneumococcal Disease: Prevalence and Prevention – A Wheel of Knowledge Challenge!

Start

Activity Details

Free CME/MOC/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
0.5 ACPE Contact Hour(s)
Released: November 15, 2021
Expires: November 14, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for this activity is family medicine physicians, internists, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the management of patients with pneumococcal disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the burden of pneumococcal disease and patient populations who are at high risk for disease.
  • Incorporate the safe and effective use of pneumococcal disease vaccination, as per Advisory Committee on Immunization Practices (ACIP) recommendations, in both normal- and high-risk patients.
  • Utilize effective strategies that educate patients about pneumococcal disease and increase their vaccine confidence.

Activity Description

Pneumococcal disease poses a burden to the community throughout the year, especially in those with chronic underlying conditions. Due to the high persistent burden of disease, pneumococcal pneumonia—particularly non-bacteremic pneumococcal pneumonia—continues to be a major public health concern. Young children and the elderly are especially at risk for pneumococcal disease and are therefore eligible for immunization in most countries. However, clinicians are often unaware of the burden of pneumococcal disease and the patient populations who are at highest risk for disease. They also may lack understanding of the safe and effective use of pneumococcal disease vaccination and may not know how to utilize effective strategies to educate patients about pneumococcal disease and increase their vaccine confidence. Moreover, clinicians may not be aware of the current guideline recommendations for best practices regarding the use of pneumococcal vaccination, and they may be unaware of the new and emerging pneumococcal vaccines, thus resulting in suboptimal care for their patients. In this game-based CME activity, participants will answer questions on the burden of pneumococcal disease, the latest ACIP recommendations regarding the optimal use of pneumococcal disease strategies in both normal- and high-risk patients, as well as strategies to educate patients about pneumococcal disease.

Activity Co-Chairs

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Consultant: Sanofi Genzyme
Speaker Contracted by Ineligible Company: Sanofi Genzyme


John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure:
Advisor: Sanofi
Speaker Contracted by Ineligible Company: Sanofi

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-026-H01-P, effective 11/15/2021. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 0.5 hour(s) credit for completing this program.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CPE
0.5 AMA PRA Category 1 Credit(s)
0.5 ABIM MOC Point(s)
0.5 ACPE Contact Hour(s)
Released: November 15, 2021
Expires: November 14, 2022
30 minutes to complete

Accredited By

This continuing medical education activity is provided by


Target Audience

The intended audience for this activity is family medicine physicians, internists, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the management of patients with pneumococcal disease.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Review the burden of pneumococcal disease and patient populations who are at high risk for disease.
  • Incorporate the safe and effective use of pneumococcal disease vaccination, as per Advisory Committee on Immunization Practices (ACIP) recommendations, in both normal- and high-risk patients.
  • Utilize effective strategies that educate patients about pneumococcal disease and increase their vaccine confidence.

Activity Description

Pneumococcal disease poses a burden to the community throughout the year, especially in those with chronic underlying conditions. Due to the high persistent burden of disease, pneumococcal pneumonia—particularly non-bacteremic pneumococcal pneumonia—continues to be a major public health concern. Young children and the elderly are especially at risk for pneumococcal disease and are therefore eligible for immunization in most countries. However, clinicians are often unaware of the burden of pneumococcal disease and the patient populations who are at highest risk for disease. They also may lack understanding of the safe and effective use of pneumococcal disease vaccination and may not know how to utilize effective strategies to educate patients about pneumococcal disease and increase their vaccine confidence. Moreover, clinicians may not be aware of the current guideline recommendations for best practices regarding the use of pneumococcal vaccination, and they may be unaware of the new and emerging pneumococcal vaccines, thus resulting in suboptimal care for their patients. In this game-based CME activity, participants will answer questions on the burden of pneumococcal disease, the latest ACIP recommendations regarding the optimal use of pneumococcal disease strategies in both normal- and high-risk patients, as well as strategies to educate patients about pneumococcal disease.

Activity Co-Chairs

Cassandra Calabrese, DO
Assistant Professor of Medicine
Rheumatology and Infectious Disease
Cleveland Clinic Foundation
Cleveland, OH

Disclosure:
Consultant: Sanofi Genzyme
Speaker Contracted by Ineligible Company: Sanofi Genzyme


John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosure:
Advisor: Sanofi
Speaker Contracted by Ineligible Company: Sanofi

Planners/Reviewers
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Jennifer Frederick, PharmD, BCPS
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosure: No relevant financial relationships to disclose.

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

Vindico Medical Education adheres to the Accreditation Council for Continuing Medical Education’s (ACCME) Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a continuing education activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.5 Medical Knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity.

This program is acceptable for 0.5 contact hour(s) of ACPE Continuing Education Credit. The ACPE Universal Program Number 0482-0000-21-026-H01-P, effective 11/15/2021. This is a knowledge-based activity, and there is no fee to attend.

Vindico Medical Education will provide pharmacist credits claimed information directly to the ACPE through CPE Monitor within 30 days.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by ACCME.

American Academy of Physician Assistants (AAPA) accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. Physician assistants may receive a maximum of 0.5 hour(s) credit for completing this program.

Instructions for Receiving Credit

To participate in this CE activity, you must read the objectives, answer the pretest questions, view the CE content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate or ACPE Statement of Credit.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non−FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Michael G. Ison, MD, MS
0.25 CME / MOC / CNE / CPE
RMEI Medical Education, LLC
Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Curbing the Potential Threat of Influenza in High-Risk Populations: The Role of Antiviral Prophylaxis and Treatment—Influenza Postexposure Prophylaxis: Don’t Overlook the High-Risk Patient

Start

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Free CME/MOC/CNE/CPE
0.25 AMA PRA Category 1 Credit(s)
0.25 ANCC contact hour(s)
0.25 ACPE contact hour(s)
0.25 ABIM MOC point(s)
Released: October 11, 2021
Expires: October 10, 2022
15 minutes to complete

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for emergency medicine, infectious disease, and primary care clinicians involved in the treatment of patients with influenza.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Identify patients who may be at high risk for influenza-related complications
  • Recognize the possible presentations of influenza in high-risk individuals
  • Assess key data available for antiviral therapies for post-exposure chemoprophylaxis and treatment of influenza in high-risk individuals
  • Recommend an appropriate antiviral agent for post-exposure chemoprophylaxis or treatment of influenza in high-risk patients with influenza

Activity Description

In this activity, experts present a case of a high-risk patient who was exposed to influenza but did not receive antiviral chemoprophylaxis. A panel discussion highlights reasons why influenza chemoprophylaxis may be overlooked in clinical practice, as well as current guideline recommendations for who should receive it, when, and for how long. Efficacy data for antiviral therapeutic options for influenza chemoprophylaxis, including oseltamivir, zanamivir, and baloxavir marboxil, is presented.

Activity Chair

Michael G. Ison, MD, MS
Medical Director, Transplant & Immunocompromised Host Infectious Diseases Service
Northwestern University Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine
Chicago, IL

Faculty

Richard K. Zimmerman, MD, MPH, MS
Professor, Department of Family Medicine
University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy. RMEI is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Michael G. Ison, MD, MS, has financial relationships with Adagio, AlloVir, Celltrion, Cidara, Genentech, Janssen, Roche, Shionogi, Viracor Eurofins (Consultant); AiCurus, Janssen, GlaxoSmithKline, Shire (Grant/Research Support paid to Northwestern University); CSL Behring, Janssen, Merck, SAB Biotherapeutics, Sequiris, Takeda (Other: Data and Safety Monitoring Board [DSMB] Member).

Richard K. Zimmerman, MD, MPH, MS, has a financial relationship with Sanofi Pasteur (Grant/Research Support).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Continuing Pharmacy Education
RMEI Medical Education, LLC designates this continuing education activity for 0.25 contact hour(s) (0.25 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008290-0000-21-003-H01-P)
Type of Activity: Knowledge

American Board of Internal Medicine Maintenance of Certification
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 medical knowledge MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Criteria for Success

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

  • Read the learning objectives and faculty disclosures
  • Participate in the activity
  • Complete the activity evaluation and attest to credit
  • Physicians claiming ABIM MOC must provide ABIM ID and month/date of birth and score 75% or higher on the post-test
  • Pharmacists claiming ACPE credit must provide NABP e-PID# and month/date of birth

For Physicians: MOC points will be submitted to ABIM profiles within 4 weeks of completion.

For Pharmacists: Transcript information will be sent to the NABP CPE Monitor® within 8 weeks.

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!

*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

0.75 CME / CNE / CPE
Postgraduate Institute for Medicine
Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder

Your Words Matter – Language Showing Compassion and Care for Women, Infants, Families, and Communities Impacted by Substance Use Disorder

Start

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2023
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Describe the effects of stigma on pregnant women and mothers.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Activity Details

Free CME/CNE/CPE/CDE
0.75 AMA PRA Category 1 Credit(s)
0.75 ANCC Contact hour(s)
0.75 ACPE Contact hour(s) (0.075 CEUs)
0.75 ADA Continuing education credit(s)
Released: July 15, 2021
Expires: October 17, 2023
45 minutes to complete

Provided By

Target Audience

This activity is intended for physicians, physician assistants, pharmacists, registered nurses, nurse practitioners/other APRNs, and dentists engaged in the care of patients with substance use disorders.

Learning Objectives

After completing this activity, the participant should be better able to:

  • Explain the effects of stigmatizing language on patients with addiction.
  • Describe the effects of stigma on pregnant women and mothers.
  • Compare common terminology and assess which terms should be used or avoided and why.
  • Integrate person-first, non-stigmatizing language into everyday practice.
  • Identify terms to use and terms to avoid when speaking to patients about addiction.

Activity Description

This CME/CE activity highlights your role in helping destigmatize addiction and substance use disorder and reduce negative bias among pregnant women and mothers. The activity has background information and tips for providers on language to use or avoid.

Course Director

Michelle Corbin, MBA
NIDAMED Coordinator
National Institute on Drug Abuse
Rockville, MD

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The PIM planners and others have nothing to disclose.

The following planners and others have nothing to disclose: Hendree Jones, Michelle Corbin from the National Institute on Drug Abuse, Melinda Campopiano, Erika Capinguian, Susan Hayashi, and Laura Nolan from JBS International, Inc.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and the National Institute on Drug Abuse. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.75 contact hour(s).

Continuing Pharmacy Education
Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008162-9999-21-2679-H01-P)
Type of Activity: Knowledge

Continuing Dental Education
Postgraduate Institute for Medicine is an ADA CERP Recognized Provider. ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education. ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of the credit hours by boards of dentistry. Concerns or complaints about a CE provider may be directed to the provider or to the Commission for Continuing Education Provider Recognition at ADA.org/CERP.

Postgraduate Institute for Medicine designates this activity for 0.75 continuing education credit(s).

Statement of Commercial Support

There is no commercial funding for this activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Hardware/Software Requirements

Content is accessible regardless of internet browser. However, the Google Chrome browser often performs best.

Policy on Privacy and Confidentiality

Please see final activity for the policy on privacy and confidentiality that relates to this internet activity.

Contact Information for Questions About the Activity

If you have questions regarding the certification of this activity, please contact PIM via email at inquiries@pimed.com.

Peter Dicpinigaitis, MD, FCCP
1.0 CME / MOC / CC
Vindico Medical Education
Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Multidisciplinary Perspective in Chronic Cough: Streamlining Care for Your Patients

Start

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC/CC
1.0 AMA PRA Category 1 Credit(s)
1.0 ABIM MOC
1.0 ABOHNS Continuing Certification
Released: June 30, 2021
Expires: June 29, 2022
60 minutes to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for this activity is family medicine physicians, internists, allergists, immunologists, gastroenterologists, otolaryngologists, pulmonologists, and other health care professionals involved in the management of patients with chronic cough.

Learning Objectives

Upon successful completion of the activity, participants should be better able to:

  • Outline multidisciplinary strategies that can streamline the health care journey for patients with chronic cough.
  • Review the latest mechanistic understanding regarding chronic cough and the implications for emerging treatments.
  • Evaluate the latest clinical evidence regarding emerging treatment strategies for patients with chronic cough.

Activity Description

In this educational video, experts examine the patient's health care journey and discuss multidisciplinary approaches to assessment and management of chronic cough. Faculty will review current unmet needs and discuss emerging treatment options to improve the quality of life for patients with refractory chronic cough. This expert panel features an interactive learning platform to encourage engagement and enhanced learning.

Statement of Educational Need

Chronic cough lasting more than 8 weeks impacts up to 13% of the US population. While chronic cough may be associated with any number of pulmonary or extrapulmonary conditions, 70% of patients with chronic cough experience at least 3 clinical encounters to obtain a diagnosis and 53% remain undiagnosed. Additionally, over half of patients who receive treatment note that their symptoms remain uncontrolled, significantly affecting daily activities, sleep, and quality of life. With new treatments on the horizon for managing chronic cough, it is imperative that clinicians have a mechanistic understanding of chronic cough and are able to identify patients who may benefit from emerging therapies.

Agenda

A Look at the Health Care Journey of Patients With Chronic Cough
John J. Russell, MD, FAAFP

Current Unmet Needs in Chronic Cough
Kenneth W. Altman, MD, PhD, FACS

Treatments on the Horizon for Refractory Chronic Cough
Peter Dicpinigaitis, MD, FCCP

Activity Chair

Peter Dicpinigaitis, MD, FCCP
Professor of Medicine, Albert Einstein College of Medicine
Division of Critical Care Medicine, Montefiore Medical Center
Director, Montefiore Cough Center
Bronx, NY

Disclosures:
Consulting Fee: Bayer, Bellus, Merck, Shionogi

Faculty

Kenneth W. Altman, MD, PhD, FACS
Chair, Department of Otolaryngology – Head & Neck Surgery
Geisinger Health System
Danville, PA
Professor, Geisinger Commonwealth School of Medicine
Scranton, PA

Disclosures:
Consulting Fee: AXDEV

John J. Russell, MD, FAAFP
Clinical Professor of Family and Community Medicine
Sidney Kimmel Medical College
Thomas Jefferson University
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA

Disclosures:
Consulting Fee: Bayer, GlaxoSmithKline, Sanofi Pasteur
Speakers Bureau: Sanofi Pasteur

Reviewer
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosures: No relevant financial relationships to disclose.

Vindico Medical Education Staff
Disclosures: No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information is accurate at the time of content development.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:

  • 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program; and
  • 1.0 Part II self-assessment credit in the American Board of Otolaryngology – Head and Neck Surgery’s (ABOHNS) Continuing Certification program (formerly known as MOC).

It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM or ABOHNS credit.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Merck & Co., Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages